A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML
Nour Sabiha Naji(Johns Hopkins University), Theodoros Karantanos(The University of Texas MD Anderson Cancer Center), Amy E. DeZern(Johns Hopkins University), Brandy Perkins(Johns Hopkins University), Teodora Supeanu(Johns Hopkins University), Ivana Gojo(Johns Hopkins University), Bogdan C. Paun(Johns Hopkins University), Theodora Chatzilygeroudi(Johns Hopkins University), Suman Paul(Johns Hopkins University), Tushar D. Nichakawade(Howard Hughes Medical Institute), Gabriel Ghiaur(Johns Hopkins University), J. David Peske(University of Virginia), Zanshé Thompson(University of South Carolina), Yoon‐Kyo An(Johns Hopkins University), Taha Ahmedna(Howard Hughes Medical Institute), Mark J. Levis(Johns Hopkins University), Styliani Karanika(The University of Texas MD Anderson Cancer Center), Li Luo(Johns Hopkins University), Richard J. Jones(The University of Texas MD Anderson Cancer Center), Xinghan Zeng(Johns Hopkins University), Bum Seok Lee(Johns Hopkins University), Evangeline Watson(Howard Hughes Medical Institute), Melanie Klausner(Johns Hopkins University), Linda Resar(Johns Hopkins University)
Cited by 1
Related Papers
VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION
|Transplantation|1987|914
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
|Oncogene|2013|879
Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations
|Nature|2015|501
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide
|Blood|2015|299
Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia
|Biology of Blood and Marrow Transplantation|2014|234